Redmile Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Redmile Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,219,616	Closed	-$66.3M	–	78
2017 Q2	$66.3M	Buy	+2,219,616	New	+$54.8M	4.04%	6

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Redmile Group's JUNO Position: Q3 2017 in Review

Redmile Group sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 2,219,616 shares — an estimated $66.3M sold.

Redmile Group first reported a position in JUNO in Q2 2017 and held it in 1 quarter. The position peaked at $66.3M in Q2 2017. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

Redmile Group reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Redmile Group sold 2,219,616 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $66.3M.
Redmile Group first reported a position in Juno Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
Redmile Group's Juno Therapeutics, Inc. position peaked at $66.3M in Q2 2017.
210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Redmile Group's 13F filing for Q3 2017, filed 14 Nov 2017.